SCHEMBL23217010

SCHEMBL23217010

CCOC(=O)CC(=O)Nc1ccc(S(=O)(=O)N2CCN(c3cccc(C(F)(F)F)c3)CC2)cc1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.57
TP53 P04637 1/20 0.57
ALDH1A1 P00352 7/20 0.56
LMNA P02545 4/20 0.56
GAA P10253 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
KMT2A Q03164 2/20 0.56
POLB P06746 1/20 0.55
HTT P42858 1/20 0.54
MEN1 O00255 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
TRPV4 Q9HBA0 1/20 0.52
TSHR P16473 1/20 0.52
HSD17B10 Q99714 2/20 0.52
ATM Q13315 1/20 0.51
KDM4E B2RXH2 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23217102 0.86 ALDH1A1 (0.58) MAPTALDH1A1LMNAGAASMN1; SMN2
SCHEMBL30889354 0.86 ALDH1A1 (0.58) MAPTALDH1A1LMNAGAASMN1; SMN2
SCHEMBL23228915 0.86 LMNA (0.53) MAPTALDH1A1LMNAGAASMN1; SMN2
SCHEMBL23217100 0.84 MAPT (0.70) MAPTALDH1A1LMNAGAASMN1; SMN2
SCHEMBL23217016 0.81 HTT (0.60) MAPTALDH1A1LMNAGAASMN1; SMN2
SCHEMBL30889350 0.80 MAPT (0.57) MAPTALDH1A1LMNAGAASMN1; SMN2
SCHEMBL23217034 0.80 MAPT (0.57) MAPTALDH1A1LMNAGAASMN1; SMN2
SCHEMBL1870289 0.79 F13A1 (0.72) MAPTALDH1A1LMNAGAASMN1; SMN2
SCHEMBL23217117 0.79 MAPT (0.53) MAPTALDH1A1LMNAGAASMN1; SMN2
SCHEMBL30005576 0.79 TRPV4 (0.55) MAPTALDH1A1LMNAGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240124400-A1 LPXH TARGETING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME DUKE UNIVERSITY (US) 2024-04-18 US disclosed
WO-2021072369-A1 LPXH TARGETING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME DUKE UNIVERSITY (US) 2021-04-15 WO disclosed
WO-2021072369-A1 LPXH TARGETING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME DUKE UNIVERSITY (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124400-A1 LPXH TARGETING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME CFH, LPAR3, CBR3 MAPT 4754/4885TP53 2811/4885ALDH1A1 3931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.